Skip to content
Government Federal, Medical Health Aged Care

Private hospital financial review confirms serious viability issues

Catholic Health Australia 2 mins read

Catholic Health Australia (CHA) welcomes the federal government’s report on the Private Hospital Sector Financial Viability Health Check released today, which confirms the sector is facing serious viability issues.

 

“This report confirms what we have been saying for a long time — that the private health sector is under severe and unprecedented funding pressure, especially in mental health and maternity care,” said Catholic Health Australia Director of Health Policy Dr Katharine Bassett.

 

“We thank the government for undertaking this important review and committing to swiftly identifying both short-term and long-term solutions.

 

“We look forward to working with all sector stakeholders, including insurers, medical groups, patients and independent experts, to ensure private hospitals continue to provide choice and high-quality care, and alleviate pressure on the public system.”     

 

CHA has proposed several short-term solutions to maintaining viability. These include:

  • governments purchasing services from the private hospital sector to reduce public waiting lists
  • governments helping to fund wage growth in private hospitals
  • reducing the capital reserve requirements for private health insurers to increase the flow of funding into the system
  • reforms to the 2025 premium round to ensure hospital costs are reflected in premium increases
  • government incentives to bring down out-of-pocket costs for maternity care

“Now we know the extent and seriousness of the problem facing private healthcare, the whole sector needs to move quickly and cooperatively to implement solutions in the national interest. The establishment of the Private Health CEO Forum is a welcomed step to achieving this,” said Dr Bassett.

 

CHA strongly advocated for the government’s private health check. Our consultations with the government throughout the process were led by Cabrini Health CEO Sue Williams and Calvary Healthcare CEO Martin Bowles AO PSM.

 

Notes to editors: Catholic Health Australia (CHA) is Australia’s largest non-government grouping of health and aged care services accounting for 63 hospitals and approximately 10 per cent of hospital-based healthcare in Australia. Our members, who are not-for-profit, also provide around 30 percent of private hospital care, 5 percent of public hospital care, 12 percent of aged care facilities, and 20 percent of home care and support for the elderly.


Contact details:

Charlie Moore: 0452 606 171

More from this category

  • Government Federal, Taxation
  • 08/12/2025
  • 10:11
Australian Taxation Office

ATO returns over $1 billion in unpaid super to employees

The Australian Taxation Office (ATO) has released new data, revealing $1.1billion in unpaid super has been returned to nearly a million individual’s super funds in 2024–25. Deputy Commissioner Ben Kelly said the latest figures show the ATO’s compliance efforts to protect employee’s super entitlements are continuing to pay dividends. ‘We issued over 200,000proactive reminders and prompts, helping more employers stay on track, as well as taking stronger action against those employers who failed to comply.' The ATO raised almost $800million in Superannuation Guarantee Charge (SGC) liabilities, through: 120,000reminders to employers More than 70,000prompts to employers approximately 15,000audit cases. While most…

  • Medical Health Aged Care
  • 08/12/2025
  • 10:11
BeOne Medicines Ltd.

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLL Sonrotoclax in combination with BRUKINSA demonstrated rapid…

  • Contains:
  • Medical Health Aged Care
  • 08/12/2025
  • 09:40
Miltenyi Biomedicine

Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting

DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL)1Zamto-cel was well-tolerated in the majority of patients. DALY 2-EU included a high-risk study population, characterized by older age and clinically high-risk disease featuresA 12-day manufacturing time resulted in a vein-to-vein time of 14-16 days, reducing the likelihood for bridging therapy.BERGISCH GLADBACH, Germany, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Miltenyi Biomedicine today announced results from the pivotal DALY 2-EU trial evaluating the efficacy and safety of zamtocabtagene autoleucel (zamto-cel) compared with standard chemoimmunotherapy (R-GemOx or Pola-BR) in patients with…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.